Microba receives $6.08 million R&D Tax Incentive Refund
Released
Released
Announcement PDF
ASX Announcement
10 April 2024
Microba receives $6.08 million R&D Tax Incentive Refund
•
$6,089,165 R&D Tax Incentive received for Research & Development Activities conducted during FY23
•
The $6.08m FY23 R&D Tax Incentive adds to Microba’s strong financial position of $27.85m in Cash or
equivalents as at 31 December 2023
Microba Life Sciences Limited (ASX: MAP) (“Microba”) is pleased to announce that the Company has received a $6,089,165
Research & Development (R&D) Tax Incentive refund relating to R&D activities completed in the 2022/2023 financial year. The
Australian Government’s R&D Tax Incentive program provides companies with a 43.5% refundable tax offset for eligible R&D
activities.
In addition to Microba’s Australian Research & Development activities being eligible for the R&D Tax Incentive, Microba has also
received four separate Advanced Overseas Findings from AusIndustry, which pre-approve eligible overseas expenditure for
research and development activities across its Inflammatory Bowel Disease (IBD) and Autoimmune Diseases therapeutic
programs. These four Advanced Overseas Findings cover total eligible overseas expenditure across FY22, FY23, FY24 and FY25.
Microba’s Chief Executive Officer, Dr. Luke Reid, commented on the receipt of the R&D Tax Incentive, “We sincerely appreciate
this ongoing support from the Australian Government. We believe that Microba’s clinical stage therapeutics and diagnostic
gastrointestinal tests can make a positive impact on Australian lives in the future, and the R&D Tax Incentive Program is assisting
Microba to make this a reality”.
This announcement has been authorised for release by the Chair and Chief Executive Officer.
For further information, please contact:
Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com
Investor / Media Relations
E: investor@microba.com
W: https://ir.microba.com/
Join our Investor Mailing List
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology
for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major
chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through
partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome,
health and disease for the development of new health solutions.
For more information visit: www.microba.com
Microba encourages all current investors to go paperless by registering their details with the designated registry service
provider, Automic Group.
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
Share your feedback
Discover